CommercialCoverageMedium impact
06.02.46a, Rapid Whole Exome Sequencing (rWES) and Rapid Whole Genome Sequencing (rWGS) for Diagnosis of Genetic Disorders
Independence Blue Cross·Genetics, Pediatrics, Internal Medicine +3 more·Medical Policy
Effective date
Dec 19, 2025
We identified it
Jun 19, 2026
Summary
Policy 06.02.46a establishes coverage criteria for Rapid Whole Exome Sequencing (rWES) and Rapid Whole Genome Sequencing (rWGS) for diagnosis of genetic disorders. This recent reissue (effective 12/19/2025) replaces previous guidance and requires billing teams to understand medical necessity requirements, prior authorization protocols, and covered indications for these advanced genetic testing services.
Action Required
By 12/19/2025: Billing and clinical teams must review policy 06.02.46a for specific coverage criteria, medical necessity requirements, and prior authorization mandates for rWES and rWGS testing. Update encounter documentation templates to capture required clinical indicators supporting medical necessity. Verify with the payer which CPT codes are used for rWES and rWGS billing at your practice and confirm whether prior authorization is required before claim submission. Implement verification procedures to confirm patient eligibility and authorization status prior to ordering or billing these services. Failure to comply with medical necessity documentation and prior authorization requirements may result in claim denials.